Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a crossover study of XPF-001 in inherited erythromelalgia
2009-015619-42Phase 2Terminated
- Sponsor
- Xenon Pharmaceuticals
- Start
- Oct 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial in erythromelalgia comparing XPF-001 sequences with Placebo sequences (2 arms). Primary endpoint: TOTPAR-6 pain relief. Started Oct 2009; status: terminated.
02
Drugs
funapide
03
Conditions
erythromelalgia
Beyond the preview
Go deeper on 2009-015619-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015619-42.